AstraZeneca COVID-19 vaccine found to be 79% effective in U.S. trials

By Nikita Chaurasia  | Date: 2021-03-23

AstraZeneca COVID-19 vaccine found to be 79% effective in U.S. trials

The COVID-19 vaccine co-developed by AstraZeneca Plc, a British-Swedish multinational biotechnology company, and scientists at Oxford University, has reportedly passed the U.S. clinical trials with 79% effectiveness in preventing symptomatic disease in over 32,000 participants.

AstraZeneca announced that it would keep analyzing data and make relevant provisions in a bid to request emergency use authorization (EUA) in the United States in the upcoming weeks. The move, if approved by authorities, will make the vaccine available for American citizens.

The shot has already been widely administered across several European countries. The U.S. trials, however, involved a sample size study of 32,000 participants - the largest-ever number of people to be studied for the effectiveness of AstraZeneca’s COVID-19 vaccine.

The study could reinstate public confidence in the vaccine, after speculations regarding its efficacy arose following serious blood-clotting issues in a small number of individuals in Europe who received the shot, sources claimed. The trials conducted in the U.S. found no increased risk of serious blood clotting among the vaccinated population.

AstraZeneca reportedly mentioned that the vaccine had an 80% rate of efficacy among elder participants aged 65 years and above.

In the past few weeks, blood clotting fears led several European countries, such as Italy and Germany, to temporarily discontinue the use of the vaccine. However, most countries resumed its usage after European and U.K. medicine authorities reiterated the shot's effectiveness despite the rare incidences of blood clotting, which were not proven to be connected to the vaccine.

The EU regulators claimed to not have ruled out the possibility of blood clots but emphasized that the vaccine is a shield preventing severe symptoms and death and that its benefits outweigh risks.

In other news, AstraZeneca has recently cut the number of doses delivered to the EU after blaming production delays in the Netherland and Belgium. The EU had imposed export controls for coronavirus vaccines in March this year to stop a consignment of 2,50,000 doses that were to be shipped from Italy to Australia.

Source Credits –

https://www.marketwatch.com/story/astrazeneca-us-covid-vaccine-trial-79-effective-2021-03-22?link=MW_latest_news

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Pacific Island pushes Japan to delay wastewater release from Fukushima

Pacific Island pushes Japan to delay wastewater release from Fukushima

By Nikita Chaurasia

Pacific Island nations have reportedly pushed Japan to postpone the release of Fukushima nuclear power plant wastewater due to concerns that it may pollute fishing grounds. An appeal was made on Wednesday when Japan announced that treated sewage f...

Activist groups take Danone to court over excessive use of plastics

Activist groups take Danone to court over excessive use of plastics

By Nikita Chaurasia

Danone, the French bottled water and yogurt firm, is reportedly being sued in court by three environmental activists’ groups for failing to cut its plastic footprint significantly. According to the groups, the maker of Evian and Volvic miner...

Bosch expands security with dashcams designed for rideshare drivers

Bosch expands security with dashcams designed for rideshare drivers

By Nikita Chaurasia

Bosch, the German technology company, has reportedly expanded its security footprint in the ridesharing market with the launch of its latest security dashcams. At CES 2023, Las Vegas, the German tech firm unveiled a new integrated smart camera on ...

Australia: PM Albanese denies potential $450M payout to Rio Tinto

Australia: PM Albanese denies potential $450M payout to Rio Tinto

By Nikita Chaurasia

Australia's Prime Minister Anthony Albanese has reportedly denied rumors that Rio Tinto and its partners could receive a $450 million settlement for the Gladstone power station, which would bring the total compensation for the coal price limit to...

UK: Firms still struggle with post-Brexit trading and red tape

UK: Firms still struggle with post-Brexit trading and red tape

By Nikita Chaurasia

Businesses in the UK are still reportedly grappling after two years following the beginning of post-Brexit trading, as suggested by a new report. According to the British Chambers of Commerce (BCC), firms are still battling increased red tape and ...